Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
Sana, CAMP4 ditch clinical-stage assets for preclinical hopefuls
Sana, CAMP4 and Crinetics have used the third quarter to refocus their pipelines on the most promising candidates.
James Waldron
Nov 7, 2025 8:13am
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
Nov 6, 2025 1:26pm
Boehringer's deal frenzy continues with $570M autoimmune pact
Nov 4, 2025 8:00am
Celltrion pens $744M pact for 2 preclinical autoimmune drugs
Nov 4, 2025 6:15am
Boehringer returns to Kyowa with €640M pact for autoimmune drug
Oct 30, 2025 6:03am
Zenas autoimmune drug prompts 95% drop in lesions in MS study
Oct 27, 2025 9:25am
